Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902172 | 0.89 | PDE3B (0.55) | PDE3BPDE3AP2RY12MAOAGAA | |
| SCHEMBL4665908 | 0.86 | HDAC1 (0.55) | MAOATHRATHRBKDM4EHSD17B10 | |
| SCHEMBL6599615 | 0.85 | HDAC1 (0.59) | PDE3BPDE3AP2RY12MAOATHRA | |
| SCHEMBL5447736 | 0.81 | PDE3B (0.59) | PDE3BPDE3AP2RY12GAAKDM4E | |
| SCHEMBL29843519 | 0.81 | PTPN7 (0.58) | PDE3BPDE3AP2RY12MAOAGAA | |
| SCHEMBL2942026 | 0.81 | PTPN7 (0.58) | PDE3BPDE3AP2RY12MAOAGAA | |
| SCHEMBL1196091 | 0.80 | LTA4H (0.55) | MAOATHRATHRBGAAHSD17B10 | |
| SCHEMBL10174322 | 0.78 | GAA (0.57) | PDE3BPDE3AP2RY12GAAKDM4E | |
| SCHEMBL27370553 | 0.78 | PTPN7 (0.63) | PDE3BPDE3AP2RY12GAAKDM4E | |
| SCHEMBL29282185 | 0.77 | TSHR (0.47) | PDE3BPDE3AP2RY12GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-108203438-B | Fused imidazole compounds having indoleamine 2,3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | disclosed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| EP-2658851-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Cadila Healthcare Limited (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | disclosed |
| WO-2012090220-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
| US-20080234349-A1 | PPAR active compounds | PLEXXIKON INC. | 2008-09-25 | — | — | US | disclosed |
| EP-1931658-A2 | 1 , 4 AND 1 , 5-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030574-A2 | 1 , 4 AND 1 , 5-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | LIPC, HMGCR, PCSK9 | PDE3B 1042/4885PDE3A 1296/4885P2RY12 3819/4885 |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | PDE3B 2166/4885PDE3A 2514/4885P2RY12 4620/4885 |
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | PDE3B 628/4885PDE3A 837/4885P2RY12 858/4885 |
| US-20080234349-A1 | PPAR active compounds | PPARG, PPARA, PPARD | PDE3B 1127/4885PDE3A 1038/4885P2RY12 989/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | PDE3B 1497/4885PDE3A 1827/4885P2RY12 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.